HIV患者中增强型蛋白酶抑制剂的治疗药物监测:血药浓度不可测与病毒学失败风险
该研究基于治疗药物监测(TDM)登记和回顾性随访,评估HIV阳性患者中利托那韦及增强型蛋白酶抑制剂(PI)血浆浓度不可测的患病率及其与48周病毒学失败风险的关系。依从组病毒控制率81.9%,部分不依从组71.7%,不依从组53.1%(P=0.001)。基线HIV RNA>50 copies/mL、基因型敏感性评分≤2、较低CD4最低值和未处于依从组是48周HIV RNA>50 copies/mL的独立预测因素。
要点
- TDM可发现PI和利托那韦血药浓度不可测,提示不完全依从。
- 依从组48周病毒控制率高于部分不依从组和不依从组。
- 未处于依从组是48周病毒学失败的独立预测因素。
核心结论
- 测量PI和利托那韦血浆水平可发现不完全治疗依从性。
- TDM可能是识别需要依从性促进干预患者的有用工具。
研究设计与样本
- TDM登记研究纳入723例患者,共收集2468份样本。
主要发现
- 部分不依从组中阿扎那韦/利托那韦患者比例(7.9%)高于达芦那韦/利托那韦(每日两次2%和每日一次1.9%)及洛匹那韦/利托那韦(1.5%)(P<0.001)。
- 随访研究中依从组病毒控制率81.9%(167/204),部分不依从组71.7%(33/46),不依从组53.1%(17/32)(P=0.001)。
- 多因素分析显示基线HIV RNA>50 copies/mL(P<0.001)、基因型敏感性评分≤2(P=0.001)、较低CD4最低值(P=0.003)和未处于依从组(P=0.029)是48周HIV RNA>50 copies/mL的独立预测因素。
临床怎么用
- 对选定HIV阳性患者进行PI和利托那韦TDM,以识别不完全依从者。
- 对TDM提示部分不依从或不依从的患者,考虑实施依从性促进干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic drug monitoring (TDM) of antiretroviral drugs is performed in selected HIV-positive patients. The aim of this study was to estimate the prevalence of undetectable plasma concentrations of ritonavir and boosted PIs and to evaluate the association between those and the 48 week risk of virological failure. METHODS: A TDM registry study and a retrospective follow-up study were conducted. Plasma concentrations were measured through validated methods. According to PI and ritonavir concentrations, patients were stratified as adherent, partially non-adherent or non-adherent. Virological outcome was evaluated 48 weeks afterwards. RESULTS: The TDM registry study included 2468 samples collected from 723 patients (68.1% male, median age 43.5 years). Eighty-seven samples (3.5%, 74 patients) and 68 samples (2.8%, 52 patients) were in the partially non-adherent and non-adherent groups, respectively; more patients on atazanavir/ritonavir (7.9%) versus darunavir/ritonavir (2% twice daily and 1.9% once daily) and lopinavir/ritonavir (1.5%; P < 0.001) were observed in the partially non-adherent group. Two hundred and ninety patients were included in the follow-up study (64.1% male, median age 40 years). Patients in the adherent group had a higher chance of viral control [81.9% (167/204)] versus the partially non-adherent group and the non-adherent group [71.7% (33/46) and 53.1% (17/32), respectively; P = 0.001]. Based on multivariate analysis, baseline HIV RNA >50 copies/mL ( P < 0.001), genotypic susceptibility score ≤2 ( P = 0.001), lower nadir CD4 cell count ( P = 0.003) and not being in the adherent group ( P = 0.029) were independent predictors of HIV RNA >50 copies/mL at 48 weeks. CONCLUSIONS: The measurement of PI and ritonavir plasma levels can uncover incomplete compliance with treatment; TDM may represent a useful tool for identifying patients in need of adherence-promoting interventions.
引用
- Calcagno A, Pagani N, Ariaudo A, et al. Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. J Antimicrob Chemother. 2017. PMID: 28333285. doi:10.1093/jac/dkx052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。